| 21494621 |
Inhibition of anaplastic lymphoma kinase (ALK) activity provides a therapeutic approach for CLTC-ALK-positive human diffuse large B cell lymphomas
Cerchietti, L,
Damm-Welk, C,
Vater, I,
Klapper, W,
Harder, L,
Pott, C,
Yang, SN,
Reiter, A,
Siebert, R,
Melnick, A,
Woessmann, W
|
PLoS One |
2011 |
| 21948233 |
ALK mutations conferring differential resistance to structurally diverse ALK inhibitors
Heuckmann, JM,
Hölzel, M,
Sos, ML,
Heynck, S,
Balke-Want, H,
Koker, M,
Peifer, M,
Weiss, J,
Lovly, CM,
Grütter, C,
Rauh, D,
Pao, W,
Thomas, RK
|
Clin. Cancer Res. |
2011 |
| 23239810 |
Crizotinib-resistant NPM-ALK mutants confer differential sensitivity to unrelated Alk inhibitors
Ceccon, M,
Mologni, L,
Bisson, W,
Scapozza, L,
Gambacorti-Passerini, C
|
Mol. Cancer Res. |
2013 |
| 22570254 |
Identification of anaplastic lymphoma kinase as a potential therapeutic target in ovarian cancer
Ren, H,
Tan, ZP,
Zhu, X,
Crosby, K,
Haack, H,
Ren, JM,
Beausoleil, S,
Moritz, A,
Innocenti, G,
Rush, J,
Zhang, Y,
Zhou, XM,
Gu, TL,
Yang, YF,
Comb, MJ
|
Cancer Res |
2012 |
| 17185414 |
Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK
Galkin, AV,
Melnick, JS,
Kim, S,
Hood, TL,
Li, N,
Li, L,
Xia, G,
Steensma, R,
Chopiuk, G,
Jiang, J,
Wan, Y,
Ding, P,
Liu, Y,
Sun, F,
Schultz, PG,
Gray, NS,
Warmuth, M
|
Proc. Natl. Acad. Sci. U.S.A. |
2007 |
